Gutierrez-Bautista, Juan FranciscoRodriguez-Nicolas, AntonioRosales-Castillo, AntonioLopez-Ruz, Miguel AngelMartin-Casares, Antonia MariaFernandez-Rubiales, AlonsoAnderson, PerGarrido, FedericoRuiz-Cabello, FranciscoLopez-Nevot, Miguel Angel2025-01-072025-01-072022-06-131684-1182https://hdl.handle.net/10668/26262Background: Human leukocyte antigen (HLA) plays an important role in immune responses to infections, especially in the development of acquired immunity. Given the high degree of polymorphisms that HLA molecules present, some will be more or less effective in controlling SARS-CoV-2 infection. We wanted to analyze whether certain polymorphisms may be involved in the protection or susceptibility to COVID-19.Methods: We studied the polymorphisms in HLA class I (HLA-A,-B and-C) and II (HLA-DRB1 and HLA-DQB1) molecules in 450 patients who required hospitalization for COVID-19, creating one of the largest HLA-typed patient cohort to date.Results: Our results show that there is no relationship between HLA polymorphisms or haplotypes and susceptibility or protection to COVID-19.Conclusion: Our results may contribute to resolve the contradictory data on the role of HLA polymorphisms in COVID-19 infection. Copyright 2021, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/HLA polymorphismsCOVID-19SARS-CoV-2Hla class-iStudy of HLA-A,-B,-C,-DRB1 and-DQB1 polymorphisms in COVID-19 patientsresearch article34475005open access10.1016/j.jmii.2021.08.0091995-9133https://doi.org/10.1016/j.jmii.2021.08.009814795400006